FDA Panel Endorses DFMO for Kids' High-Risk Neuroblastoma in

Large improvement in event-free survival, but questions linger about sources of data

Related Keywords

Colorado , United States , Los Angeles , Nicole Drezner , Shahab Asgharzadeh , Charles Bankhead , University Of Colorado Cancer Center , Oncologic Drugs Advisory Committee , Christopher Lieu , Colorado Cancer Center , Hospital Los Angeles , Medpage Today ,